Back Login to subscribe 🔔 Set Alert

BBIO BridgeBio Pharma, Inc. Common Stock

Sector: Healthcare

Industry: Biotechnology

15 min delay

Today's News Sentiment

Loading...

Upcoming Earnings

Loading...

BBIO Fundamental Data

Loading...

Similar Companies

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

BBIO Insider Transactions

Loading insider data…

BBIO News

Date	Headline	Sentiment
	Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care	62.37%
	Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations	72.6%
	Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156	90.37%
	BridgeBio Announces Presentation Of Attruby Amyloid Heart Disease Data At HFSA October 9-12, Including Real-World Comparison vs. Tafamidis	79.13%
	BridgeBio Announces Presentation Of Additional Phase 3 Encaleret Data In Genetic Hypocalcemia ADH1 At ASBMR On October 11	90.94%
	BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia	78.81%
	Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima	76.68%
	BridgeBio Pharma shares are trading lower. The company reported data showing acoramidis reduced the risk of early clinical worsening versus tafamidis in ATTR-CM.	90.4%
	BridgeBio Says Acoramidis Associated With 34% Lower Risk Of Clinical Worsening vs. Tafamidis In Real-World Study	84.15%